HONG KONG, June 2, 2021 - (ACN Newswire) - UOB-Kay Hian issued a report raising the target price of China Shineway Pharmaceutical (02877.HK) from HK$8.44 to HK$11.8, an increase of 39.8%, on a BUY rating.
China Shineway Pharmaceutical 1Q21 revenue was RMB 744 million, surging 37% YoY. All business segments continued to experience robust recovery.
FINET News H.K.
https://www.finet.hk/
Copyright 2021 ACN Newswire . All rights reserved.
China Shineway Pharmaceutical 1Q21 revenue was RMB 744 million, surging 37% YoY. All business segments continued to experience robust recovery.
FINET News H.K.
https://www.finet.hk/
Copyright 2021 ACN Newswire . All rights reserved.